로딩 중…
StockDiggingStockDigging

Natera, Inc.

NTRA· NASDAQ
$369.39+0.84%
2026-09-18

Financials

Valuation Metrics

Natera, Inc.'s Market Cap is $52.90B. At end of 2025 it was $31.32B. Ranked #309 of 3,121 in US market (top 10%), #83 of 1,463 on NASDAQ (top 6%), #16 of 205 in Health Care Equipment & Services (top 8%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$52.90B
Revenue$2.71B
Net Income$-192M
Total Assets$2.66B
Net Assets$1.82B
Employees6,138
Value
P/B29.04x
P/S19.54x
FCF Yield0.14%
Profitability
ROE-10.56%
ROA-7.24%
Op. Margin-10.70%
Revenue Growth37.82%
Financial Health
Debt Ratio45.90%
Total Debt$238M
FCF$72M
Cash$1.09B
Current Ratio3.00x
Performance
1Y Return105.38%
1M Return13.63%
From 52W High0.00%
1Y MDD-28.20%
Trading
Volume3,514,831 shares
Trading Value$1.29B
Per Share
EPS$-1.34
BPS$12.72

Company Info

CEO Steven Leonard Chapman
Employees 6,138
HQ Austin, US

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.